Previous close | 65.27 |
Open | 65.50 |
Bid | 65.37 x 800 |
Ask | 65.50 x 800 |
Day's range | 64.64 - 66.35 |
52-week range | 64.64 - 87.87 |
Volume | |
Avg. volume | 7,349,480 |
Market cap | 81.577B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 14.54 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (4.72%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Q1 2024 Gilead Sciences Inc Earnings Call